News stories about Celgene (NASDAQ:CELG) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celgene earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8955813238091 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Barclays upped their price objective on Celgene from $135.00 to $140.00 and gave the company an “equal weight” rating in a research report on Friday, October 13th. Sanford C. Bernstein began coverage on Celgene in a report on Tuesday, October 17th. They issued an “outperform” rating and a $162.00 price target on the stock. BMO Capital Markets increased their price target on Celgene from $160.00 to $167.00 and gave the stock a “positive” rating in a report on Tuesday, October 17th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Celgene in a report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $130.35.

Celgene (CELG) opened at $91.02 on Friday. Celgene has a 52 week low of $90.98 and a 52 week high of $147.17. The stock has a market capitalization of $71,660.00, a P/E ratio of 25.21, a P/E/G ratio of 0.68 and a beta of 1.49. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 64.14% and a net margin of 22.38%. The company had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. During the same quarter in the prior year, the firm earned $1.61 earnings per share. Celgene’s revenue was up 16.9% compared to the same quarter last year. analysts expect that Celgene will post 7.68 EPS for the current year.

In other news, insider Mark J. Alles acquired 3,260 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were bought at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the purchase, the insider now directly owns 178,904 shares in the company, valued at $16,441,277.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.95% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Celgene (CELG) Getting Somewhat Positive Media Coverage, Report Finds” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with's FREE daily email newsletter.